SLDB

Solid Biosciences Inc

Add to Watchlist

Advanced Chart

5.955

-0.075(-1.244%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.000

Open

6.000

VWAP

5.96

Vol

27.10K

Mkt Cap

469.55M

Low

5.950

Amount

161.60K

EV/EBITDA(TTM)

Total Shares

38.38M

202.39M

EV/OCF(TTM)

P/S(TTM)

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.502

-14.98%

-0.469

-53.11%

-0.441

-44.22%

Estimates Revision

The market is revising No Change the revenue expectations for Solid Biosciences Inc. (SLDB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 105.34%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.23%

In Past 3 Month

Stock Price

Go Up

+105.34%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 15.44 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.955

Low

10.00

Averages

15.44

High

20.00

Current: 5.955

Low

10.00

Averages

15.44

High

20.00

H.C. Wainwright

Buy

maintain

2025-06-18

Reason

H.C. Wainwright

Price Target

2025-06-18

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on Solid Biosciences (SLDB) after Sarepta (SRPT) disclosed a second patient death due to acute liver failure following treatment with Elevidys. The news underscores the favorable safety profile of Solid's SGT-003, the analyst tells investors in a research note. The firm believes SGT-003 has the most favorable safety profile among the leading Duchenne muscular dystrophy gene therapies either in clinic or in the market. Wainwright expects a meaningful share of ambulatory patients to transition from Elevidys to SGT-003.

Barclays

Overweight

downgrade

$15 -> $10

2025-05-16

Reason

Barclays

Price Target

$15 -> $10

2025-05-16

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Solid Biosciences to $10 from $15 and keeps an Overweight rating on the shares. The company's Q1 report was largely incremental, with continued pipeline progress, the analyst tells investors in a research note.

Piper Sandler

Overweight

downgrade

$20 -> $17

2025-05-16

Reason

Piper Sandler

Price Target

$20 -> $17

2025-05-16

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Solid Biosciences to $17 from $20 and keeps an Overweight rating on the shares following quarterly results and update. Dosing is ongoing in the Phase 1/2 INSPIRE DUCHENNE trial, with next data update in about 10-12 patients expected in Q4 2025 after planned FDA meeting to discuss the accelerated approval pathway. In parallel, Solid Biosciences is gearing up for the initiation of its first-in-human Phase 1b Friedreich's Ataxia study with SGT-212 in Q4 2025, which will include both ambulatory and non-ambulatory patients, Piper adds.

Wedbush

Outperform

downgrade

$18 -> $17

2025-05-16

Reason

Wedbush

Price Target

$18 -> $17

2025-05-16

downgrade

Outperform

Reason

Wedbush lowered the firm's price target on Solid Biosciences to $17 from $18 on higher share count, while keeping an Outperform rating on the shares. The firm says the most important in the company's update was that all key development timelines remain on track. Solid Biosciences continues to anticipate making an FDA meeting request this summer to discuss SGT-003 accelerated approval pathway options and plans to complete dosing in by 20 subjects by Q4 2025. All in, Wedbush remains impressed by the early INSPIRE data and sees limited credit being assigned at present levels.

JP Morgan

Anupam Rama

Buy

Maintains

$12 → $11

2025-03-13

Reason

JP Morgan

Anupam Rama

Price Target

$12 → $11

2025-03-13

Maintains

Buy

Reason

JPMorgan lowered the firm's price target on Solid Biosciences to $11 from $12 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.

HC Wainwright & Co.

Arthur He

Strong Buy

Maintains

$16 → $20

2025-03-10

Reason

HC Wainwright & Co.

Arthur He

Price Target

$16 → $20

2025-03-10

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Solid Biosciences Inc (SLDB.O) is -3.18, compared to its 5-year average forward P/E of -2.78. For a more detailed relative valuation and DCF analysis to assess Solid Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.78

Current PE

-3.18

Overvalued PE

-0.64

Undervalued PE

-4.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.72

Current EV/EBITDA

-1.30

Overvalued EV/EBITDA

0.61

Undervalued EV/EBITDA

-2.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

29.33

Current PS

0.00

Overvalued PS

76.99

Undervalued PS

-18.34